EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Fecal microbiota transplantation: current challenges and future landscapes

Abbas Yadegar iD, Haggai Bar-Yoseph, Tanya Marie Monaghan iD, Sepideh Pakpour, Andrea Severino, Ed J Kuijper iD, Wiep Klaas Smits iD, Elisabeth M Terveer, Sukanya Neupane, Ali Nabavi-Rad, Javad Sadeghi iD, Giovanni Cammarota und 5 weitere

Clinical Microbiology Reviews · 13.06.2024 · 37 (2)

DOI: 10.1128/cmr.00060-22 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 13.06.2024. Verfasst von Abbas Yadegar und 16 weiteren Autor:innen. Beteiligte Einrichtung: Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical …. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Gastrointestinal Microbiome. Die Arbeit wurde bisher 375-mal zitiert (Crossref) und nennt 425 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Canadian Government | Canadian Institutes of Health Research (CIHR), NIHR | NIHR Nottingham Biomedical Research Centre (BRC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the importance of gut microbial homeostasis in maintaining health, there has been considerable interest in developing innovative therapeutic strategies for restoring gut microbiota. One such approach, fecal microbiota transplantation (FMT), is the main “whole gut microbiome replacement” strategy and has been integrated into clinical practice guidelines for treating recurrent Clostridioides difficile infection (rCDI). Furthermore, the potential application of FMT in other indications such as inflammatory bowel disease (IBD), metabolic syndrome, and solid tumor malignancies is an area of intense interest and active research. However, the complex and variable nature of FMT makes it challenging to address its precise functionality and to assess clinical efficacy and safety in different disease contexts. In this review, we outline clinical applications, efficacy, durability, and safety of FMT and provide a comprehensive assessment of its procedural and administration aspects. The clinical applications of FMT in children and cancer immunotherapy are also described. We focus on data from human studies in IBD in contrast with rCDI to delineate the putative mechanisms of this treatment in IBD as a model, including colonization resistance and functional restoration through bacterial engraftment, modulating effects of virome/phageome, gut metabolome and host interactions, and immunoregulatory actions of FMT. Furthermore, we comprehensively review omics technologies, metagenomic approaches, and bioinformatics pipelines to characterize complex microbial communities and discuss their limitations. FMT regulatory challenges, ethical considerations, and pharmacomicrobiomics are also highlighted to shed light on future development of tailored microbiome-based therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fecal Microbiota TransplantationGastrointestinal MicrobiomeHumansClostridium InfectionsInflammatory Bowel DiseasesAnimals

Stichwörter der Autor:innen

Clostridioides difficile infectiondonor screeningfecal microbiota transplantationhuman microbiomemicrobial engraftment

Autor:innen und Institutionen

  • Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Gastroenterology, Rambam Health Care Campus, Haifa, Israel.
  • Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • National Institute for Health Research Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.
  • Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
  • School of Engineering, Faculty of Applied Sciences, UBC, Okanagan Campus, Kelowna, British Columbia, Canada.

ORCID-Profile: Abbas Yadegar, Tanya Marie Monaghan, Ed J Kuijper, Wiep Klaas Smits, Javad Sadeghi, Dina Kao

Förderung

  • Canadian Government | Canadian Institutes of Health Research (CIHR)
  • NIHR | NIHR Nottingham Biomedical Research Centre (BRC)

Zitieren

APA

Yadegar, A., Bar-Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., Sadeghi, J., Cammarota, G., Ianiro, G., Nap-Hill, E., Leung, D., Wong, K., & Kao, D. (2024). Fecal microbiota transplantation: current challenges and future landscapes. Clinical Microbiology Reviews, 37(2). https://doi.org/10.1128/cmr.00060-22

Vancouver

Yadegar A, Bar-Yoseph H, Monaghan TM, Pakpour S, Severino A, Kuijper EJ, et al. Fecal microbiota transplantation: current challenges and future landscapes. Clinical Microbiology Reviews. 2024;37(2). doi:10.1128/cmr.00060-22

BibTeX
@article{Yadegar2024,
  author = {Yadegar, Abbas and Bar-Yoseph, Haggai and Monaghan, Tanya Marie and Pakpour, Sepideh and Severino, Andrea and Kuijper, Ed J and Smits, Wiep Klaas and Terveer, Elisabeth M and Neupane, Sukanya and Nabavi-Rad, Ali and Sadeghi, Javad and Cammarota, Giovanni and Ianiro, Gianluca and Nap-Hill, Estello and Leung, Dickson and Wong, Karen and Kao, Dina},
  title = {Fecal microbiota transplantation: current challenges and future landscapes},
  journal = {Clinical Microbiology Reviews},
  year = {2024},
  volume = {37},
  number = {2},
  doi = {10.1128/cmr.00060-22}
}
Kostenlos starten →